People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Other Health Care, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ExploraMed NC7, Inc. | — | Other Health Care | Series C | $181.5M | $751.6M | 2015 |
| Neotract Inc | — | Other Health Care | Series C | $117.5M | $293.0M | 2012 |
| Svelte Medical Systems Inc | — | Biotechnology | Series C | $113.1M | $163.7M | 2021 |
| Arstasis Inc | — | Other | Series B | $102.3M | $274.1M | 2009 |
| Vascular Therapies Inc | — | Biotechnology | Series B | $89.2M | $471.3M | 2012 |
| Vibrynt, INc | — | Other Health Care | Series A | $14.3M | $55.5M | 2012 |
| ExploraMed IV, L.L.C. | — | Other | Series A | $6.6M | $99.9M | 2011 |
ROBERT CROCE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ROBERT CROCE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Anderson | 4 | 24 |
| Ryan Drant | 4 | 24 |
| Joshua Makower | 4 | 10 |
| John Nehra | 3 | 11 |
| Robert W. Croce | 3 | 7 |
| Joshua W. Makower | 3 | 4 |
| Somu Subramaniam | 2 | 17 |
| Robert K. Anderson | 2 | 6 |
| ROGER GUIDI | 2 | 5 |
| Robert Flanagan | 2 | 4 |
| Ryan W. Drant | 2 | 4 |
| Michael Carusi | 1 | 7 |
| David Fischell | 1 | 6 |
| Robert Fischell | 1 | 6 |
| Heather Preston | 1 | 6 |
| Andrew Midler | 1 | 6 |
| Lewis C. Pell | 1 | 5 |
| Douglas Roeder | 1 | 5 |
| David Auth | 1 | 5 |
| David Amerson | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.